The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

The biotech sector has found its footing again after several difficult years. The equal-weighted S&P Biotechnology ETF (XBI) has staged an impressive rebound, helped by a revival in risk appetite, ...

This biotech powerhouse could maintain its strength for the long term.

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Alumis Inc., a San Francisco-based biotech, completed its IPO in June last year, raising ~$250m, and focuses on developing TYK2 inhibitors ESK-001 and A-005. Alumis' ESK-001 is in Phase 3 trials for ...

The MarketWatch News Department was not involved in the creation of this content. BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging artificial intelligence ...

At first glance, the European Commission’s Biotech Act proposal may appear as another sectoral initiative aimed at boosting innovation. On closer reading, however, it signals something far more ...

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, announces the launch of Derisq™, ...